Literature DB >> 16862439

Engineering human cytochrome P450 enzymes into catalytically self-sufficient chimeras using molecular Lego.

Vikash Rajnikant Dodhia1, Andrea Fantuzzi, Gianfranco Gilardi.   

Abstract

The membrane-bound human cytochrome P450s have essential roles in the metabolism of endogenous compounds and drugs. Presented here are the results on the construction and characterization of three fusion proteins containing the N-terminally modified human cytochrome P450s CYP2C9, CY2C19 and CYP3A4 fused to the soluble NADPH-dependent oxidoreductase domain of CYP102A1 from Bacillus megaterium. The constructs, CYP2C9/BMR, CYP2C19/BMR and CYP3A4/BMR are well expressed in Escherichia coli as holo proteins. The chimeras can be purified in the absence of detergent and the purified enzymes are both active and correctly folded in the absence of detergent, as demonstrated by circular dichroism and functional studies. Additionally, in comparison with the parent P450 enzyme, these chimeras have greatly improved solubility properties. The chimeras are catalytically self-sufficient and present turnover rates similar to those reported for the native enzymes in reconstituted systems, unlike previously reported mammalian cytochrome P450 fusion proteins. Furthermore the specific activities of these chimeras are not dependent on the enzyme concentration present in the reaction buffer and they do not require the addition of accessory proteins, detergents or phospholipids to be fully active. The solubility, catalytic self-sufficiency and wild-type like activities of these chimeras would greatly simplify the studies of cytochrome P450 mediated drug metabolism in solution.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16862439     DOI: 10.1007/s00775-006-0144-3

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  58 in total

1.  Association of cytochromes P450 with their reductases: opposite sign of the electrostatic interactions in P450BM-3 as compared with the microsomal 2B4 system.

Authors:  D R Davydov; A A Kariakin; N A Petushkova; J A Peterson
Journal:  Biochemistry       Date:  2000-05-30       Impact factor: 3.162

2.  Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.

Authors:  H Yamazaki; K Inoue; P M Shaw; W J Checovich; F P Guengerich; T Shimada
Journal:  J Pharmacol Exp Ther       Date:  1997-11       Impact factor: 4.030

3.  Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae.

Authors:  W R Brian; M A Sari; M Iwasaki; T Shimada; L S Kaminsky; F P Guengerich
Journal:  Biochemistry       Date:  1990-12-25       Impact factor: 3.162

4.  Amino acid 305 determines catalytic center accessibility in CYP3A4.

Authors:  S M Fowler; R J Riley; M P Pritchard; M J Sutcliffe; T Friedberg; C R Wolf
Journal:  Biochemistry       Date:  2000-04-18       Impact factor: 3.162

5.  Expression, purification, and characterization of a catalytically active human cytochrome P450 1A2:rat NADPH-cytochrome P450 reductase fusion protein.

Authors:  A Parikh; F P Guengerich
Journal:  Protein Expr Purif       Date:  1997-04       Impact factor: 1.650

6.  Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity.

Authors:  G C Ibeanu; B I Ghanayem; P Linko; L Li; L G Pederson; J A Goldstein
Journal:  J Biol Chem       Date:  1996-05-24       Impact factor: 5.157

7.  Engineering proteins, subcloning and hyperexpressing oxidoreductase genes.

Authors:  K Darwish; H Y Li; T L Poulos
Journal:  Protein Eng       Date:  1991-08

Review 8.  The many roles of cytochrome b5.

Authors:  John B Schenkman; Ingela Jansson
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

9.  High-level expression in Escherichia coli of enzymatically active fusion proteins containing the domains of mammalian cytochromes P450 and NADPH-P450 reductase flavoprotein.

Authors:  C W Fisher; M S Shet; D L Caudle; C A Martin-Wixtrom; R W Estabrook
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

10.  The effects of cytochrome b5, NADPH-P450 reductase, and lipid on the rate of 6 beta-hydroxylation of testosterone as catalyzed by a human P450 3A4 fusion protein.

Authors:  M S Shet; K M Faulkner; P L Holmans; C W Fisher; R W Estabrook
Journal:  Arch Biochem Biophys       Date:  1995-04-20       Impact factor: 4.013

View more
  18 in total

1.  Engineering and analysis of a self-sufficient biosynthetic cytochrome P450 PikC fused to the RhFRED reductase domain.

Authors:  Shengying Li; Larissa M Podust; David H Sherman
Journal:  J Am Chem Soc       Date:  2007-10-04       Impact factor: 15.419

Review 2.  Natural strategies for the spatial optimization of metabolism in synthetic biology.

Authors:  Christina M Agapakis; Patrick M Boyle; Pamela A Silver
Journal:  Nat Chem Biol       Date:  2012-05-17       Impact factor: 15.040

Review 3.  Engineering cytochrome P450 enzyme systems for biomedical and biotechnological applications.

Authors:  Zhong Li; Yuanyuan Jiang; F Peter Guengerich; Li Ma; Shengying Li; Wei Zhang
Journal:  J Biol Chem       Date:  2019-12-06       Impact factor: 5.157

4.  Electron transfer in the complex of membrane-bound human cytochrome P450 3A4 with the flavin domain of P450BM-3: the effect of oligomerization of the heme protein and intermittent modulation of the spin equilibrium.

Authors:  Dmitri R Davydov; Elena V Sineva; Srinivas Sistla; Nadezhda Y Davydova; Daniel J Frank; Stephen G Sligar; James R Halpert
Journal:  Biochim Biophys Acta       Date:  2009-12-21

5.  Single-step fermentative production of the cholesterol-lowering drug pravastatin via reprogramming of Penicillium chrysogenum.

Authors:  Kirsty J McLean; Marcus Hans; Ben Meijrink; Wibo B van Scheppingen; Aad Vollebregt; Kang Lan Tee; Jan-Metske van der Laan; David Leys; Andrew W Munro; Marco A van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-17       Impact factor: 11.205

6.  Understanding uncoupling in the multiredox centre P450 3A4-BMR model system.

Authors:  Danilo Degregorio; Sheila J Sadeghi; Giovanna Di Nardo; Gianfranco Gilardi; Sandro P Solinas
Journal:  J Biol Inorg Chem       Date:  2010-09-21       Impact factor: 3.358

7.  Structure of the open conformation of a functional chimeric NADPH cytochrome P450 reductase.

Authors:  Louise Aigrain; Denis Pompon; Solange Moréra; Gilles Truan
Journal:  EMBO Rep       Date:  2009-05-29       Impact factor: 8.807

8.  The effect of mutation of F87 on the properties of CYP102A1-CYP4C7 chimeras: altered regiospecificity and substrate selectivity.

Authors:  Chiung-Kuang J Chen; Tatiana Kh Shokhireva; Robert E Berry; Hongjun Zhang; F Ann Walker
Journal:  J Biol Inorg Chem       Date:  2008-04-08       Impact factor: 3.358

9.  Kinetics of electron transfer in the complex of cytochrome P450 3A4 with the flavin domain of cytochrome P450BM-3 as evidence of functional heterogeneity of the heme protein.

Authors:  Harshica Fernando; James R Halpert; Dmitri R Davydov
Journal:  Arch Biochem Biophys       Date:  2007-12-07       Impact factor: 4.013

10.  Scanning chimeragenesis: the approach used to change the substrate selectivity of fatty acid monooxygenase CYP102A1 to that of terpene omega-hydroxylase CYP4C7.

Authors:  Chiung-Kuang J Chen; Robert E Berry; Tatjana Kh Shokhireva; Marat B Murataliev; Hongjung Zhang; F Ann Walker
Journal:  J Biol Inorg Chem       Date:  2009-08-30       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.